Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Jan;33(1):14-8.
doi: 10.4103/0971-6203.39419.

Dosimetry and treatment planning of Occu-Prosta I-125 seeds for intraocular lesions

Affiliations

Dosimetry and treatment planning of Occu-Prosta I-125 seeds for intraocular lesions

Suresh Chaudhari et al. J Med Phys. 2008 Jan.

Abstract

Intraocular malignant lesions are frequently encountered in clinical practice. Plaque brachytherapy represents an effective means of treatment for intraocular lesions. Recently Radiopharmaceutical Division, BARC, Mumbai, has indigenously fabricated reasonable-cost I-125 sources. Here we are presenting the preliminary experience of dosimetry of sources, configuration of treatment planning system (TPS) and quality assurance (QA) for eye plaque therapy with Occu-Prosta I-125 seeds, treated in our hospital, for a patient with ocular lesions. I-125 seeds were calibrated using well-type chamber. BrachyVision TPS was configured with Monte Carlo computed radial dose functions and anisotropy functions for I-125 sources. Dose calculated by TPS at different points in central axis and off axis was compared with manually calculated dose. Eye plaque was fabricated of 17 karat pure gold, locally. The seeds were arranged in an outer ring near the edge of the plaque and in concentric rings throughout the plaque. The sources were manually digitized on the TPS, and dose distribution was calculated in three dimensions. Measured activity using cross-calibrated well-type chamber was within +/-10% of the activity specified by the supplier. Difference in TPS-calculated dose and manually calculated dose was within 5%. Treatment time calculated by TPS was in concordance with published data for similar plaque arrangement.

Keywords: I-125; dosimetry and planning; eye plaque; intraocular lesions.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: None declared.

Figures

Figure 1
Figure 1
Sectional diagram of Occu-Prosta seed
Figure 2
Figure 2
Anatomy of Eye and eye plaque placement
Figure 3
Figure 3
Magnified view of eye plaque placed over scleral surface
Figure 4
Figure 4
A & B shows dose distribution around the plaque in frontal at 5mm depth & side view
Figure 5
Figure 5
Radial dose fall off on the plaque central axis

Similar articles

Cited by

References

    1. Freire JE, De Potter P, Brady LW, Longton WA. Brachytherapy in primary ocular tumors. Semin Surg Oncol. 1997;13:167–76. - PubMed
    1. Char DH, Quivey JR, Castro JR, Kroll S, Phillips T. Helium ions versus I-125 plaque therapy in the management of uveal melanoma: A prospective, randomized, dynamically balanced trial. Ophthalmology. 1993;100:1547–54. - PubMed
    1. Nag S, Quivey JM, Earle JD, Followill D, Fontanesi J, Finger PT, et al. The American brachytherapy society recommendations for brachytherapy of uveal melanomas. Int J Radiat Oncol Biol Phys. 2003;56:544–55. - PubMed
    1. Diener-West M, Earle JD, Fine SL, Hawkins BS, Moy CS, Reynolds SM, et al. The COMS randomized trial of Iodine-125 brachytherapy for choroidal melanoma, III: Initial mortality findings. Arch Ophthalmol. 2001;119:969–82. - PubMed
    1. Melia BM, Abramson DH, Albert DM, Boldt HC, Earle JD, Hanson WF, et al. Collaborative Ocular Melanoma Study Randomized Trial of I-125 brachytherapy for medium choroidal melanoma, I. Visual acuity after 3 years: COMS Report No 16. Ophthalmology. 2001;108:348–66. - PubMed